Document is current
Any future updates will be listed below
-
Authors
Li, Yen-Der
Ma, Michelle W.
Hassan, Muhammad Murtaza
Hunkeler, Moritz http://orcid.org/0000-0003-0246-1188
Teng, Mingxing http://orcid.org/0000-0001-6574-1764
Puvar, Kedar
Rutter, Justine C. http://orcid.org/0000-0002-0851-0887
Lumpkin, Ryan J.
Sandoval, Brittany
Jin, Cyrus Y.
Schmoker, Anna M. http://orcid.org/0000-0003-2830-5650
Ficarro, Scott B.
Cheong, Hakyung
Metivier, Rebecca J. http://orcid.org/0000-0001-9929-6857
Wang, Michelle Y.
Xu, Shawn
Byun, Woong Sub http://orcid.org/0000-0003-4676-3698
Groendyke, Brian J.
You, Inchul
Sigua, Logan H.
Tavares, Isidoro
Zou, Charles
Tsai, Jonathan M.
Park, Paul M. C. http://orcid.org/0000-0002-9380-8548
Yoon, Hojong
Majewski, Felix C. http://orcid.org/0000-0001-5330-5922
Sperling, Haniya T. http://orcid.org/0009-0006-6624-1597
Marto, Jarrod A. http://orcid.org/0000-0003-2086-1134
Qi, Jun http://orcid.org/0000-0002-1461-3356
Nowak, Radosław P. http://orcid.org/0000-0002-0605-0071
Donovan, Katherine A. http://orcid.org/0000-0002-8539-5106
Słabicki, Mikołaj http://orcid.org/0000-0001-6317-9296
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | National Institutes of Health (R01HL082945, P01CA066996, P50CA206963, R35CA253125, K00CA253754, K99CA287069, U24DK116204, R01CA219850, R01CA233800, R21CA247671, 1S10OD028697-01, R01CA262188, P01CA066996)
Harvard Institutional Stipend; Genevieve Castrodale Carpenter Graduate Financial Aid Fund
Chleck Fellowship Foundation; Fujifilm Fellowship
Cancer Prevention and Research Institute of Texas (RR220012)
Massachusetts Life Sciences Center
Mark Foundation for Cancer Research
Departmental funds from Stanford Chemical and Systems Biology and Stanford Cancer Institute
Mark Foundation for Cancer Research 19-001-ELA
- License Information
-
More Information
Article History
Received: 27 February 2024
Accepted: 5 June 2024
First Online: 29 July 2024
Competing interests
: B.L.E. has received research funding from Celgene, Deerfield, Novartis and Calico Life Sciences and consulting fees from AbbVie. He is a member of the scientific advisory board (SAB) for and a shareholder of Neomorph, Inc., TenSixteen Bio, Skyhawk Therapeutics and Exo Therapeutics. E.S.F. is a founder, SAB member and equity holder of Civetta Therapeutics, Lighthorse Therapeutics, Proximity Therapeutics and Neomorph, Inc. (board of directors). He is an equity holder in and SAB member for Avilar Therapeutics and Photys Therapeutics and a consultant to Novartis, Sanofi, EcoR1 Capital and Deerfield. The Fischer laboratory receives or has received research funding from Deerfield, Novartis, Ajax, Interline and Astellas. N.S.G. is a founder, SAB member and equity holder in Syros, C4, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, CobroVentures, GlaxoSmithKline, Larkspur (board member), Shenandoah (board member) and Soltego (board member). The Gray laboratory receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. M.S. has received research funding from Calico Life Sciences. K.A.D. receives or has received consulting fees from Kronos Bio and Neomorph, Inc. J.Q. is an equity holder of Epiphanes and Talus Bioscience and receives or has received research funding from Novartis. J.A.M. is a founder and equity holder of and advisor to Entact Bio, serves on the SAB of 908 Devices and receives or has received sponsored research funding from Vertex, AstraZeneca, Taiho, Springworks, TUO Therapeutics and Bruker. Y.-D.L. is currently employed by Leerink Partners. M.W.M. is currently employed by Novartis Venture Fund. K.P. is currently employed by AbbVie. R.J.L. is currently employed by Flagship Pioneering. B.J.G. is currently employed by Blueprint Medicines. I.Y. is currently employed by Matchpoint Therapeutics. The remaining authors declare no competing interests.
